Brian Sullivan - Elevation Oncology VP Devel
| ELEV Stock | USD 0.60 0.01 1.64% |
Insider
Brian Sullivan is VP Devel of Elevation Oncology
| Address | 101 Federal Street, Boston, MA, United States, 02110 |
| Phone | 716 371 1125 |
| Web | https://elevationoncology.com |
Brian Sullivan Latest Insider Activity
Tracking and analyzing the buying and selling activities of Brian Sullivan against Elevation Oncology stock is an integral part of due diligence when investing in Elevation Oncology. Brian Sullivan insider activity provides valuable insight into whether Elevation Oncology is net buyers or sellers over its current business cycle. Note, Elevation Oncology insiders must abide by specific rules, including filing SEC forms every time they buy or sell Elevation Oncology'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Brian Sullivan over six months ago Disposition of 765897 shares by Brian Sullivan of Celcuity LLC subject to Rule 16b-3 | ||
Brian Sullivan over six months ago Celcuity LLC exotic insider transaction detected | ||
Brian Sullivan over six months ago Bona fide gift to Brian Sullivan of 85000 shares of Celcuity LLC subject to Section 16 | ||
Brian Sullivan over six months ago Celcuity LLC exotic insider transaction detected |
Elevation Oncology Management Efficiency
The company has return on total asset (ROA) of (0.2546) % which means that it has lost $0.2546 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6367) %, meaning that it created substantial loss on money invested by shareholders. Elevation Oncology's management efficiency ratios could be used to measure how well Elevation Oncology manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.54 in 2024. Return On Capital Employed is likely to drop to -0.56 in 2024. At this time, Elevation Oncology's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to climb to about 1.2 M in 2024, whereas Other Current Assets are likely to drop slightly above 3.4 M in 2024.Similar Executives
| Found 11 records | INSIDER Age | ||
| Daren Ure | Hepion Pharmaceuticals | N/A | |
| Avani Kanubaddi | Enveric Biosciences | 51 | |
| Sharen Pyatetskaya | Hepion Pharmaceuticals | ||
| Todd MD | Hepion Pharmaceuticals | 55 | |
| Ibrahim MD | Enveric Biosciences | 55 | |
| Launa Aspeslet | Hepion Pharmaceuticals | N/A | |
| MBA IV | Enveric Biosciences | 68 | |
| Stephen MD | Hepion Pharmaceuticals | N/A | |
| Joseph Tucker | Enveric Biosciences | 55 | |
| Peter Facchini | Enveric Biosciences | 60 | |
| BSc BSc | Hepion Pharmaceuticals | 66 | |
Management Performance
| Return On Equity | -0.64 | ||||
| Return On Asset | -0.25 |
Elevation Oncology Leadership Team
Elected by the shareholders, the Elevation Oncology's board of directors comprises two types of representatives: Elevation Oncology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Elevation. The board's role is to monitor Elevation Oncology's management team and ensure that shareholders' interests are well served. Elevation Oncology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Elevation Oncology's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joseph Ferra, Chief Officer | ||
| Valerie MD, Chief Officer | ||
| RPh PharmD, President, Founder | ||
| Ryan Bloomer, Head CMC | ||
| Biren Shah, Senior Development | ||
| Brian Sullivan, VP Devel | ||
| Candice Masse, Senior Relations | ||
| Robert Yang, Senior Counsel | ||
| PMP CPA, CFO Secretary | ||
| David Dornan, Chief Officer |
Elevation Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Elevation Oncology a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.64 | ||||
| Return On Asset | -0.25 | ||||
| Current Valuation | (36.38 M) | ||||
| Shares Outstanding | 59.12 M | ||||
| Shares Owned By Insiders | 0.24 % | ||||
| Shares Owned By Institutions | 77.96 % | ||||
| Number Of Shares Shorted | 6.21 M | ||||
| Price To Earning | 0.16 X | ||||
| Price To Book | 0.51 X | ||||
| EBITDA | (41.47 M) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Elevation Stock Analysis
When running Elevation Oncology's price analysis, check to measure Elevation Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elevation Oncology is operating at the current time. Most of Elevation Oncology's value examination focuses on studying past and present price action to predict the probability of Elevation Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elevation Oncology's price. Additionally, you may evaluate how the addition of Elevation Oncology to your portfolios can decrease your overall portfolio volatility.